Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital of University of Science and Technology of China

About this trial

To assess the effect of endovascular thrombectomy alone compared to intravenous thrombolysis plus endovascular thrombectomy in acute basilar artery occlusion patients within 4.5 hours from onset on efficacy and safety outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery;

Time from stroke onset to randomization within 4.5 hours of estimated time of basilar artery occlusion;

Patient's age ≥ 18 years;

Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In case of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery;

Disqualifiers

CT or MR evidence of intracerebral hemorrhage (the presence of < 10 microbleeds is allowed);

Pre-stroke modified Rankin scale (mRS) score ≥ 2;

Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT/ CTA-Source Images<6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) <5;

Pregnant or lactating women;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intravenous thrombolysis

    Drug

    Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.

  • Endovascular thrombectomy

    Procedure/Surgery

    Endovascular thrombectomy

Treatment groups

338 Participants
are divided into 2 treatment groups
Group A: Endovascular thrombectomy aloneExperimental treatment 1 intervention
Group B: Intravenous thrombolysis plus endovascular thrombectomyActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days)

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 (± 14 days) after procedure

Secondary outcomes

1

Proportion of patients with modified Rankin Score 0-3 at day 90 (±14 days)

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 (± 14 days) after procedure
2

Proportion of patients with modified Rankin Score 0-1 at day 90 (±14 days)

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 (± 14 days) after procedure
3

Proportion of patients with modified Rankin Score 0-4 at day 90 (±14 days)

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 (± 14 days) after procedure
4

Ordinal Shift analysis of modified Rankin Score at day 90 (±14 days)

The modified Rankin Score is an ordinal hierarchical scale ranging from 0 to 6, with higher scores indicating more severe disability.

Time frame
90 (± 14 days) after procedure

Other outcomes

1

Symptomatic intracerebral hemorrhage (sICH) within 72 hours

Symptomatic intracranial hemorrhage defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, or intraventricular hemorrhage that led to death or was observed on an imaging scan obtained 24 to 72 hours after treatment, combined with a neurologic worsening of at least 4 points from baseline on the NIHSS or from the lowest NIHSS score between baseline and 24 hours, or death from any cause within 90 days.

Time frame
Within 72 hours after procedure
2

Any intracerebral hemorrhage within 72 hours

Evaluate intracerebral hemorrhage

Time frame
Within 72 hours after procedure
3

Overall mortality at 7 (± 2 days) and 90 (± 14 days)

Evaluate death rate

Time frame
7 (± 2 days) and 90 (± 14 days) after procedure

Sponsors and contacts

Click on the lead sponsor to view all of their trials.